Esperion is a late-stage pharmaceutical company that is committed to developing and commercializing convenient, complementary, consistent, once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
Esperion has two LDL-C lowering therapies in development; the bempedoic acid / ezetimibe combination pill and bempedoic acid. Both have confirmed regulatory pathways to approval and defined global pivotal Phase 3 clinical development plans resulting in tandem New Drug Application (NDA) and Marketing Authorization Application (MAA) global regulatory approvals expected in the U.S. and Europe by the first quarter of 2020.
Esperion owns the exclusive worldwide rights to the bempedoic acid-based franchise of products in development.
- Phase Ph1